Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18-85 years~* Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be classified with either high or moderate confidence as a specific idiopathic interstitial pneumonia or other defined ILD~* Progressive disease as considered by the investigator as participants deterioration within the last 6 months, which is defined as a rate of decline in forced vital capacity (FVC) \>5% or a significant symptomatic worsening not due to cardiac, pulmonary vascular or other causes~* Extent of fibrosis \>10% on high-resolution computed tomography~* Forced vital capacity \>= 45% of predicted value~* Diffusing capacity of the lung for carbon monoxide (DLco) \>= 30% of predicted value~* Forced expiratory volume in 1 second/FVC ratio \>= 0.7~* Able to do 6-minute walk distance (6MWD) \>= 150 meters~* For women of childbearing potential: agreement to remain abstinent or use a non-hormonal or hormonal contraceptive method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the last dose of pirfenidone~* For men, agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm~Exclusion Criteria:~* Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and any ILD with an identifiable cause such as connective tissue disease-ILD, chronic hypersensitivity pneumonitis, or others~* Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level~* History of unstable angina or myocardial infarction during the previous 6 months~* Treatment with high dose systemic corticosteroids, or any immunosuppressant other than mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening period. Participants being treated with MMF should be on a stable dose that is expected to remain stable throughout the trial and was started at least 3 months prior to screening~* Participants previously treated with pirfenidone or nintedanib~* Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time within the 4 weeks of the screening period~* Drug treatment for any type of pulmonary hypertension~* Participation in a trial of an investigational medicinal product within the last 4 weeks~* Significant other organ co-morbidity including hepatic or renal impairment~* Predicted life expectancy \< 12 months or on an active transplant waiting list~* Use of any tobacco product in the 12 weeks prior to the start of screening, or any unwillingness to abstain from their use through to the Follow-up Visit~* Illicit drug or alcohol abuse within 12 months prior to screening~* Planned major surgery during the trial~* Hypersensitivity to the active substance or to any of the excipients of pirfenidone~* History of angioedema~* Concomitant use of fluvoxamine~* Clinical evidence of any active infection~* Any history of hepatic impairment, elevation of transaminase enzymes, or liver function test results as: Total bilirubin above the upper limit of normal (ULN), Aspartate aminotransferase or alanine aminotransferase \>1.5 × ULN, and Alkaline phosphatase \>2.0 × ULN~* Creatinine clearance \< 30 milliliter (mL) per minute, calculated using the Cockcroft-Gault formula~* Any serious medical condition, clinically significant abnormality on an Electrocardiogram (ECG) at screening, or laboratory test results~* An ECG with a heart rate corrected QT interval using Fridericia's formula as \>= 500 milliseconds at screening, or a family or personal history of long QT syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pirfenidone (Type: EXPERIMENTAL): Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
- Placebo (Type: EXPERIMENTAL): Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).